Pathogenesis of pulmonary hypertension caused by left heart disease
zinc and lung fibrosis :: Article Creator Nerandomilast Improves Lung Function In Progressive Pulmonary Fibrosis: FIBRONEER-ILD Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial. Nerandomilast met its primary end point of absolute change from baseline in forced vital capacity (FVC) vs placebo in the FIBRONEER-ILD trial (NCT05321082), which assessed the agent in patients with progressive pulmonary fibrosis (PPF).1 Boehringer Ingelheim will submit a new drug application for the investigational agent to the FDA and other health authorities based on the findings, according to a press release. The FIBRONEER-ILD trial was a double-blind, randomized trial that included 1178 patients in more than 40 countries, and the primary end point was absolute change from baseline in FVC (mL) at week 52 vs placebo. Topline data showed that the trial met...
